Generic Name: ponatinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Iclusig is a kinase inhibitor approved for adults with chronic myeloid leukemia or acute lymphoblastic leukemia with specific characteristic who are resistant to or cannot use other kinase inhibitors.

General Info

Iclusig targets BCR-ABL, an abnormal tyrosine kinase produced by the Philadelphia chromosome mutation in people with leukemia. It also inhibits other kinases including VEGFR, PDGFR, KIT and RET. Studies showed that Inclusig prevents proliferation of blood cells that grow out of control in people with specific types of leukemia. It was first approved in 2012.


Dosing Info:

Iclusig is a tablet taken once daily with or without food.

Side Effects

Common side effects include abdominal pain, skin rash, nausea, constipation, diarrhea, headache, fatigue and muscle and joint pain. Iclusig can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects may include blood clots and artery blockage, heart failure, liver problems, high blood pressure and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Iclusig may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 20, 2020